- Continued strong focus on cost control with improvement in first half operating loss and cash burn over 2010
- Improving 2011 guidance as result of DKK 25 million reduction in operating expenses
- Announced HuMax-CD74™ antibody-drug conjugate program with Seattle Genetics
- Decisive move to minimize future spending by winding down the zalutumumab program
In order to read Genmab’s Interim Report for the 6 months ended June 30, 2011 please see the attached file.
Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communication
T: +45 33 44 77 20
M: +45 25 12 62 60
E: r.gravesen@genmab.com
www.genmab.com
Company Announcement no. 24
CVR no. 2102 3884
Genmab A/S
Bredgade 34
1260 Copenhagen K
Denmark
